471 related articles for article (PubMed ID: 27797449)
1. Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.
Rosenberg L; Gerstrøm G; Nybo M
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):407-410. PubMed ID: 27797449
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
Sié P
Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
[TBL] [Abstract][Full Text] [Related]
4. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
[TBL] [Abstract][Full Text] [Related]
5. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
[TBL] [Abstract][Full Text] [Related]
6. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
7. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
[TBL] [Abstract][Full Text] [Related]
8. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
[TBL] [Abstract][Full Text] [Related]
9. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
10. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
[TBL] [Abstract][Full Text] [Related]
12. Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab-A Case Report.
Tireli D; He J; Nordling MM; Wienecke T
J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):e123-e125. PubMed ID: 28479184
[TBL] [Abstract][Full Text] [Related]
13. Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran.
Calabria S; Forcesi E; Dondi L; Pedrini A; Maggioni AP; Martini N
Cardiovasc Drugs Ther; 2018 Jun; 32(3):281-286. PubMed ID: 29869189
[TBL] [Abstract][Full Text] [Related]
14. Reversing the anticoagulation effects of dabigatran.
Dager WE; Banares L
Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab for dabigatran overdose.
Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Dabigatran with Idarucizumab.
Sodha NR; Sellke FW
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
[TBL] [Abstract][Full Text] [Related]
17. Idarucizumab for dabigatran overdose in a child.
Shapiro S; Bhatnagar N; Khan A; Beavis J; Keeling D
Br J Haematol; 2018 Feb; 180(3):457-459. PubMed ID: 27734469
[No Abstract] [Full Text] [Related]
18. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
Syed YY
Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
[TBL] [Abstract][Full Text] [Related]
19. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
[TBL] [Abstract][Full Text] [Related]
20. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
